• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

The CAPP II trial of aspirin in Lynch syndrome/HNPCC: is it time for everyone to be treated?
Source: Familial Cancer - January 9, 2021 Category: Cancer & Oncology Source Type: research

Review: Clinical aspects of hereditary DNA Mismatch repair gene mutations.
Abstract Inherited mutations of the DNA Mismatch repair genes MLH1, MSH2, MSH6 and PMS2 can result in two hereditary tumor syndromes: the adult-onset autosomal dominant Lynch syndrome, previously referred to as Hereditary Non-Polyposis Colorectal Cancer (HNPCC) and the childhood-onset autosomal recessive Constitutional Mismatch Repair Deficiency syndrome. Both conditions are important to recognize clinically as their identification has direct consequences for clinical management and allows targeted preventive actions in mutation carriers. Lynch syndrome is one of the more common adult-onset hereditary tumor syndro...
Source: DNA Repair - December 11, 2015 Category: Genetics & Stem Cells Authors: Sijmons RH, Hofstra RM Tags: DNA Repair (Amst) Source Type: research

Aspirin lowers risk of hereditary bowel cancer in obese people
ConclusionThis study followed up on a previous trial that found taking aspirin regularly reduced the risk of bowel cancer in people with the genetic condition Lynch syndrome (or HNPCC), which puts them at an increased risk of developing the disease. The study found being obese appears to further increase bowel cancer risk among people with this condition.It also found that BMI did not appear to have an effect on bowel cancer risk among those taking aspirin. While this might indicate that aspirin removes the effect of BMI, ideally a comparison of aspirin versus placebo in the different BMI groups is needed to further assess...
Source: NHS News Feed - August 18, 2015 Category: Consumer Health News Tags: Cancer Obesity Source Type: news

Hereditary Non-polyposis Colorectal Cancer: Prevention and Therapeutic Options
Abstract Lynch syndrome (LS), also known as hereditary non-polyposis colorectal cancer (HNPCC), is the most common hereditary colorectal cancer (CRC) syndrome. The first and foremost preventive measure is to identify patients with LS among CRC patients. This requires the screening of colorectal cancer through polymerase chain reaction-based microsatellite instability (MSI) testing or immunohistochemistry to look for a loss of expression of one of the mismatch repair (MMR) proteins and the referral of selected patients to genetic counseling. In LS patients, annual or biannual complete colonoscopy with chromoendosco...
Source: Current Colorectal Cancer Reports - March 19, 2015 Category: Cancer & Oncology Source Type: research